Peptides for Post-Surgery Recovery

Candidate profile

Adults recovering from orthopedic surgery (ACL reconstruction, rotator cuff repair, meniscectomy, joint replacement), abdominal surgery, or soft tissue procedures who want to optimize tissue healing alongside standard post-operative rehabilitation.

Rationale

Post-surgical recovery depends on angiogenesis (new blood vessel formation into healing tissue), collagen deposition and remodeling, inflammation resolution, and stem/progenitor cell recruitment. BPC-157 and TB-500 have preclinical evidence addressing each of these pathways — making them the most commonly discussed peptides for surgical recovery in integrative medicine.

Protocol

BPC-157

• Dose: 250–500 mcg
• Frequency: 2× daily (AM and PM)
• Route: subcutaneous injection near the surgical site (preferred for localized healing) or systemic subcutaneous
• Duration: begin as soon as post-operative day 1–3 (after initial hemostasis is established); continue for 4–8 weeks through the proliferative and early remodeling phases
• Evidence basis: preclinical — extensive rodent data on tendon, ligament, muscle, and bone healing; no controlled human post-surgical trial

TB-500

• Dose: 2.5–5 mg
• Frequency: 2× per week (loading phase for 2–4 weeks), then 1× per week (maintenance)
• Route: subcutaneous injection
• Duration: 6–8 weeks total
• Evidence basis: preclinical — actin-mediated cell migration; widely used in veterinary (equine) post-injury recovery

Timing considerations

• Pre-operative: some practitioners begin BPC-157 5–7 days before surgery to "prime" the healing response. No clinical data validates this approach, and any peptide that promotes angiogenesis theoretically could increase surgical bleeding risk. Discuss with the surgical team.
• Peri-operative: most protocols begin peptides 1–3 days post-operatively, once initial hemostasis is confirmed and drains are managed.
• Do not use peptides as a substitute for standard post-operative care, antibiotics, or prescribed rehabilitation protocols.

Expected trajectory

• Week 1–2: inflammation resolution phase — reduced swelling and pain may occur faster than baseline recovery
• Week 3–6: proliferative phase — enhanced collagen deposition and angiogenesis; this is where peptide effects are most theoretically impactful
• Week 6–12: remodeling phase — collagen organization and functional strength return. Peptide support typically discontinued by week 8.

Monitoring

• Standard post-operative follow-up with the surgical team (wound checks, imaging as scheduled)
• Range of motion and strength benchmarks per rehabilitation protocol
• Monitor for any unusual healing patterns — excessive granulation tissue, delayed wound closure, or signs of infection
• Blood work as appropriate: CRP for inflammation tracking, CBC for infection monitoring

Important caveats

This protocol is based on preclinical evidence and practitioner reports — no controlled human post-surgical trial has validated BPC-157 or TB-500 for this application. The peptides are not a substitute for skilled surgery, appropriate anesthesia, infection prophylaxis, or structured rehabilitation. Surgical outcomes depend primarily on surgical technique, patient health, and rehabilitation compliance. Peptides are potential adjuncts, not primary therapies.